Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

EMANATE: Setmelanotide-tutkimus potilailla, joilla on spesifisiä geenivariantteja MC4R-reitillä

maanantai 19. lokakuuta 2026 päivittänyt: Rhythm Pharmaceuticals, Inc.

Vaihe 3, satunnaistettu, kaksoissokkoutettu, lumekontrolloitu koe: Useita riippumattomia alatutkimuksia Setmelanotidesta potilailla, joilla on POMC/PCSK1-, LEPR-, NCOA1(SRC1)- tai SH2B1-geenivariantteja melanokortiini-4-reseptorireitillä

The protocol describes a randomized, double-blind, placebo-controlled trial with independent sub-studies of setmelanotide in participants with obesity and at least one of the specific gene variants in the Melanocortin-4 Receptor pathway:

  • Pro-opiomelanocortin (POMC) or proprotein convertase subtilisin/kexin type 1 (PCSK1; Sub-study 035a)
  • Leptin receptor (LEPR; Sub-study 035b)
  • Nuclear receptor coactivator 1 (NCOA1; steroid receptor coactivator 1 [SCR1]; Sub-study 035c)
  • Steroid receptor coactivator-1 homology 2 B adapter protein 1 (SH2B1; Sub-study 035d)

The objectives and endpoints are identical for these sub-studies.

Tutkimuksen yleiskatsaus

Opintotyyppi

Interventio

Ilmoittautuminen (Todellinen)

296

Vaihe

  • Vaihe 3

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskelupaikat

      • Rotterdam, Alankomaat, 3015 GD
        • Erasmus Medisch Centrum
      • Barcelona, Espanja, 08950
        • Hospital Sant Joan de Deu, Barcelona
      • Cadiz, Espanja
        • Puerta del Mar University Hospital
      • Madrid, Espanja, 28040
        • Hospital Fundación Jimenez Díaz
      • Málaga, Espanja, 29010
        • Hospital Universitario Virgen de la Victoria de Málaga
      • Valencia, Espanja, 46014
        • Hospital General de Valencia
      • Petah Tikva, Israel, 49372
        • Hasharon Hospital
      • Ramat Gan, Israel, 52621
        • Chaim Sheba MC, Safra Children's Hospital
    • Alberta
      • Edmonton, Alberta, Kanada, T6G 2E1
        • University of Alberta - Alberta Diabetes Institute (ADI)
    • Ontario
      • Toronto, Ontario, Kanada, M5G 1X8
        • The Hospital for Sick Children
      • Rio, Kreikka, 26504
        • University of Patras School of Medicine
      • San Juan, Puerto Rico, 00925-253
        • University of Puerto Rico
      • San Juan, Puerto Rico, 00927
        • Puerto Rico Consortium for Clinical Investigation, Inc.
      • Lyon, Ranska, 69677
        • GH Est Hopital Femme Mere Enfant
      • Paris, Ranska, 75651
        • Hu Pitie Salpetriere Aphp
      • Paris, Ranska, 75771
        • Hopital Armand Trousseau
      • Pessac, Ranska, 33604
        • Centre Hospitalier Universitaire (CHU) de Bordeaux
      • Saint-Denis, Ranska, 97400
        • Hôpital Félix Guyon Bellepierre
      • Toulouse, Ranska
        • CHU de Toulouse Hopital des Enfants
      • Berlin, Saksa, 10117
        • Charite - Universitatsmedizin Berlin
      • Frankfurt, Saksa, 60596
        • Endokrinologikum Frankfurt
      • Leipzig, Saksa, 04103
        • Universitaetsklinikum Leipzig
      • Ulm, Saksa, 89075
        • Universitaetsklinikum Ulm
      • Bristol, Yhdistynyt kuningaskunta, BS2 8AE
        • Bristol Royal Hospital for Children
      • Cambridge, Yhdistynyt kuningaskunta, CB2 0QQ
        • University of Cambridge
      • Liverpool, Yhdistynyt kuningaskunta, L9 7AL
        • Aintree University Hospital
      • London, Yhdistynyt kuningaskunta, W2 1NY
        • Imperial College Healthcare Trust
      • London, Yhdistynyt kuningaskunta, NW1 2PG
        • London Medical - The London Diabetes Centre
      • London, Yhdistynyt kuningaskunta, WC1E6JF
        • University College London Hospitals NHS Foundation Trust
      • Manchester, Yhdistynyt kuningaskunta, M13 9WL
        • Manchester Children's Hospital
    • Arizona
      • Phoenix, Arizona, Yhdysvallat, 85016
        • Phoenix Children's Hospital
      • Scottsdale, Arizona, Yhdysvallat, 85258
        • HonorHealth Bariatric Center
    • California
      • Los Angeles, California, Yhdysvallat, 90027
        • Children's Hospital Los Angeles
    • Colorado
      • Aurora, Colorado, Yhdysvallat, 80045
        • Children's Hospital Colorado
    • Connecticut
      • New Haven, Connecticut, Yhdysvallat, 06519
        • Yale Center for Clinical Investigation
    • Florida
      • Altamonte Springs, Florida, Yhdysvallat, 32701
        • Advent Health
      • Gainesville, Florida, Yhdysvallat, 32610
        • University of Florida
    • Georgia
      • Suwanee, Georgia, Yhdysvallat, 30024
        • InQuest Medical Research
    • Massachusetts
      • Worcester, Massachusetts, Yhdysvallat, 01655
        • UMASS Memorial Medical Center
    • Michigan
      • Ann Arbor, Michigan, Yhdysvallat, 48105
        • University of Michigan
      • Dearborn, Michigan, Yhdysvallat, 48126-2619
        • Metro Detroit Endocrinology Center
    • Minnesota
      • Rochester, Minnesota, Yhdysvallat, 55902
        • Mayo Clinic
    • Mississippi
      • Madison, Mississippi, Yhdysvallat, 39110
        • Mississippi Center for Advanced Medicine
    • Missouri
      • Chesterfield, Missouri, Yhdysvallat, 63017
        • St. Luke's Hospital
      • Kansas City, Missouri, Yhdysvallat, 64108
        • Children's Mercy
      • St Louis, Missouri, Yhdysvallat, 63130
        • Washington University in St. Louis
    • New York
      • Buffalo, New York, Yhdysvallat, 14260
        • University of Buffalo
      • New York, New York, Yhdysvallat, 10032
        • Columbia University
      • New York, New York, Yhdysvallat, 10029
        • Mount Sinai Hospital
      • New York, New York, Yhdysvallat, 10029
        • Metropolitan Hospital Center
      • Staten Island, New York, Yhdysvallat, 10306
        • Ten's Medical Center - Pediatric Endocrinology Clinic
    • Ohio
      • Cincinnati, Ohio, Yhdysvallat, 45229
        • Cincinnati Children's Hospital Medical Center
      • Cleveland, Ohio, Yhdysvallat, 44195
        • Cleveland Clinic
    • Oregon
      • Portland, Oregon, Yhdysvallat, 97239
        • Oregon Health & Science University
    • Pennsylvania
      • Danville, Pennsylvania, Yhdysvallat, 17822
        • Geisinger Clinic
      • Philadelphia, Pennsylvania, Yhdysvallat, 19104
        • Children's Hospital of Philadelphia
      • Pittsburgh, Pennsylvania, Yhdysvallat, 15213
        • UPMC Montefiore
    • Tennessee
      • Nashville, Tennessee, Yhdysvallat, 37232
        • Vanderbilt University School of Medicine
    • Texas
      • Amarillo, Texas, Yhdysvallat, 79106
        • Texas Tech
      • Houston, Texas, Yhdysvallat, 77030
        • Texas Children's Hospital
      • Houston, Texas, Yhdysvallat, 77084
        • Biopharma Informatic
      • McAllen, Texas, Yhdysvallat, 78503
        • Rio Grande Valley Endocrine Center
      • Plano, Texas, Yhdysvallat, 75093
        • Endocrine Associates of Dallas and Plano
    • Washington
      • Tacoma, Washington, Yhdysvallat, 98405
        • MultiCare Health System Institute for Research and Innovation
    • West Virginia
      • Morgantown, West Virginia, Yhdysvallat, 26506
        • West Virginia University
    • Wisconsin
      • Marshfield, Wisconsin, Yhdysvallat, 54449
        • Marshfield Clinic Research Foundation, a Division of Marshfield Clinic, Inc

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

6 vuotta - 65 vuotta (Lapsi, Aikuinen, Vanhempi Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Kaikki

Kuvaus

Inclusion Criteria:

  • Participants must have a pre-identified:

    • Heterozygous genetic variant in the POMC gene or PCSK1 gene
    • Heterozygous genetic variant in the LEPR gene
    • Homozygous, heterozygous, or compound heterozygous variant in the NCOA1 (SRC1)
    • Homozygous, heterozygous, or compound heterozygous variant in SH2B1 gene, or chromosomal 16p11.2 deletion encompassing the SH2B1 gene
  • Between 6 and 65 years of age at the time of provision of informed consent/assent

  • Obesity, defined as body mass index (BMI) ≥30 kg/m^2 for participants ≥18 years of age or BMI ≥95th percentile for age and gender for participants 6 up to 17 years of age

  • Participant and/or parent or guardian is able to understand and comply with the requirements of the study and is able to understand and sign the written informed consent/assent

  • Participant and/or parent or guardian reports that participant experienced childhood obesity, defined as the participant and/or parent or guardian reporting that the participant had obesity or was significantly overweight during childhood

  • Agree to use a highly effective form of contraception throughout the study and for 90 days following the study

  • Reported history of lifestyle intervention of diet and exercise

  • Symptoms or behaviors of hyperphagia persistent during the participant's life, including manifestations in childhood, as determined by the Investigator at screening.

Key Exclusion Criteria:

  • Weight loss of 2% or greater in the previous 3 months
  • Bariatric surgery or procedure within the previous 6 months
  • Significant psychiatric disorder(s)
  • Suicidal ideation, attempt or behavior
  • Clinically significant pulmonary, cardiac, endocrine/metabolic, hepatic or oncologic disease
  • Glycated hemoglobin (HbA1C) >10% at Screening
  • History of significant liver disease or severe kidney disease
  • History or close family history (parents or siblings) of melanoma, or participant history of oculocutaneous albinism
  • Significant dermatologic findings relating to melanoma or pre-melanoma skin lesions (excluding non-invasive basal or squamous cell lesion)
  • Participation in any clinical study with an investigational drug/device within 3 months prior to the first day of dosing
  • Previously enrolled in a clinical study involving setmelanotide or any previous exposure to setmelanotide
  • Significant hypersensitivity to any excipient in the study drug
  • If female, pregnant or breastfeeding

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Hoito
  • Jako: Satunnaistettu
  • Inventiomalli: Rinnakkaistehtävä
  • Naamiointi: Kolminkertaistaa

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: POMC or PCSK1 variant

1:1 Randomization

Subcutaneous Injection

Subcutaneous Injection

Kokeellinen: LEPR variant

1:1 Randomization

Subcutaneous Injection

Subcutaneous Injection

Kokeellinen: NCOA1 (SRC1) variant

1:1 Randomization

Subcutaneous Injection

Subcutaneous Injection

Kokeellinen: SH2B1 variant

1:1 Randomization

Subcutaneous Injection

Subcutaneous Injection

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Treatment Period: Percent Change From Baseline in Body Mass Index (BMI)
Aikaikkuna: Baseline, Week 52

BMI was calculated using participant's weight and height assessments as weight in kilograms (kg)/(height in meters [m])^2. Baseline was defined as the last available measurement taken prior to the start of treatment administration. An analysis of covariance (ANCOVA) model was used to calculate the least-squares mean with randomization stratification factors and baseline value as a covariate.

Baseline, Week 52

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Treatment Period: Percentage of Participants Who Achieved at Least a 5% Reduction in Baseline BMI
Aikaikkuna: Baseline, Week 52

BMI was calculated using participant's weight and height assessments as weight in kg/(height in m)^2. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52
Treatment Period (Participants Aged ≥18 Years): Percent Change From Baseline in Body Weight
Aikaikkuna: Baseline, Week 52

Data reported are for mean percent change from baseline in body weight measured in kg. Baseline was defined as the last available measurement taken prior to the start of treatment administration

Baseline, Week 52
Treatment Period (Participants Aged ≥12 Years): Percent Change From Baseline in Weekly Average Most Hunger Score
Aikaikkuna: Baseline, Week 52

Participants ≥12 years of age who were able to validly and reliably self-report were administered "Hunger Questions for Participants ≥12 Years of Age©." The 'most hunger' item was designed to be evaluated separately and was averaged on a weekly basis. Participants were asked 'In the last 24 hours, how hungry did you feel when you were the most hungry?' and rated their hunger on an 11-point numeric rating scale ranging from 0 to 10 (0 = not hungry at all and 10 = hungriest possible). Data reported are for mean percent change from baseline in the weekly average daily most hunger score. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52
Treatment Period: Percentage of Participants Who Achieved at Least a 10% Reduction in Baseline BMI
Aikaikkuna: Baseline, Week 52

BMI was calculated using participant's weight and height assessments as weight in kg/(height in m)^2. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52
Treatment Period (Participants <18 Years): Percent Change From Baseline in BMI Z-score
Aikaikkuna: Baseline, Week 52

BMI z-scores were calculated according to the Centers for Disease Control and Prevention (CDC) Growth Charts and according to participant's gender and age at screening. A Z-score of 0 is equal to the mean of a reference population (i.e., healthy, age and sex-matched individuals). A decrease in BMI Z-score (< 0) indicates a reduction in BMI from Baseline whereas an increase in BMI-Z score (> 0) indicated an increase in BMI from Baseline. Data reported are for mean percent change from baseline in BMI Z-score. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52
Treatment Period (Participants <18 Years): Percent Change From Baseline in BMI 95th Percentile
Aikaikkuna: Baseline, Week 52

The percentage change from baseline in BMI 95th percentile was calculated as ([BMI at Week 52 / BMI 95th percentile]) - [BMI at baseline / BMI 95th percentile])*100. BMI percentile scores are measures of relative weight adjusted for child age and gender. The percent of the BMI 95th percentile score expresses the participant's BMI as a percentage of the Centers for Disease Control (CDC) 95th percentile reference population. Data reported are for mean percent change from baseline in BMI 95th percentile. Baseline was defined as the most recent measurement prior to the first administration of study drug.

Baseline, Week 52
Treatment Period: Percent Change From Baseline in Waist Circumference
Aikaikkuna: Baseline, Week 52

The waist circumference (in centimeters [cm]) was measured according to the National Heart, Lung, and Blood Institute (NHLBI) criteria. Data reported are for mean percent change from baseline in waist circumference. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52
Treatment Period: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Aikaikkuna: Baseline up to 60 weeks

TEAEs were defined as any untoward medical occurrence temporally associated with the use of study treatment, whether or not considered related to the study treatment that happened on or after the date of the first study treatment administration. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

Baseline up to 60 weeks
Treatment Period (Participants ≥18 Years): Percent Change From Baseline in Physical Functioning Score on the Impact of Weight on Quality of Life (IWQOL)-Lite
Aikaikkuna: Baseline, Week 52

The IWQOL-Lite is a validated 31-item self-reported measure of obesity-specific quality of life questionnaire. The physical function domain comprised 11 items which had 5 response items: Always True=5, Usually True=4, Sometimes True=3, Rarely True=2, Never True=1. The score of each item was summed to calculate the raw score. The raw score range of the physical function domain was 11-55 and was transformed on a scale of 0 to 100, where 100 represented the best quality of life. The transformed score was calculated as (maximum score - raw score) / (maximum score - minimum score) *100. Data reported are for mean percent change from baseline in physical functioning score on the IWQOL-Lite. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52
Treatment Period (Participants 11 to <18 Years): Percent Change From Baseline in Physical Comfort Score on the IWQOL-Kids-Parent-Proxy
Aikaikkuna: Baseline, Week 52

The IWQOL-Kids-Parent-Proxy is a psychometrically validated 27-item self-reported measure of obesity-specific quality of life questionnaire. The physical comfort domain comprised 6 items which used a 5-point Likert scale: Always True=1, Usually True=2, Sometimes True=3, Rarely True=4, Never True=5. The items were summed to calculate the raw score. The raw score range of the physical function domain was 6-30 and was transformed on a scale of 0 to 100, where 100 represented the best quality of life. The transformed score was calculated as (maximum score - raw score) / (maximum score - minimum score) *100. Data reported are for mean percent change from baseline in Physical Comfort Score on the IWQOL-Kids-Parent-Proxy. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52
Treatment Period (Participants ≥18 Years): Percent Change From Baseline in Impact on Quality of Life Total Score on the IWQOL-Lite
Aikaikkuna: Baseline, Week 52

The IWQOL-Lite is a validated 31-item self-reported measure of obesity-specific quality of life questionnaire which comprised of 5 domains (physical function, self-esteem, sexual life, distress and work) and had 5 response items: Always True=5, Usually True=4, Sometimes True=3, Rarely True=2, Never True=1. The items were summed to calculate the raw total score. The raw total score range was 31-155 and was transformed on a scale of 0 to 100, where 100 represented the best quality of life. The transformed score was calculated as (maximum score - raw score) / (maximum score - minimum score) *100. Data reported are for mean percent change from baseline in Impact on Quality of Life Total Score on the IWQOL-Lite. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52
Treatment Period (Participants 11 to <18 Years): Percent Change From Baseline in Impact on Quality of Life Total Score on the IWQOL-Kids-Parent-Proxy
Aikaikkuna: Baseline, Week 52

The IWQOL-Kids-Parent-Proxy is a psychometrically validated 27-item self-reported measure of obesity-specific quality of life questionnaire and comprised of 4 domains (physical comfort, body esteem, social life, family relations) and used a 5-point Likert scale: Always True=1, Usually True=2, Sometimes True=3, Rarely True=4, Never True=5. The items were summed to calculate the raw total score. The raw total score range was 27 to 135 and was transformed on a scale of 0 to 100, where 100 represented the best quality of life. The transformed score was calculated as (maximum score - raw score) / (maximum score - minimum score) *100. Data reported are for mean percent change from baseline in Impact on Quality of Life Total Score on the IWQOL-Kids-Parent-Proxy. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52
Treatment Period: Percent Change From Baseline in Body Weight in Setmelanotide Initial Responders Versus Placebo
Aikaikkuna: Baseline, Week 52

Initial responders were defined as setmelanotide treated participants with ≥5% body weight loss (≥18 years of age) or a decrease in BMI by ≥3% (<18 years of age) at the time of consecutive 12 weeks with the increased 3.0 mg/day or with final increased dose level. Data reported are for mean percent change from baseline in body weight measured in kg. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Tutkijat

  • Opintojen puheenjohtaja: David Meeker, MD, Rhythm Pharmaceuticals, Inc.

Julkaisuja ja hyödyllisiä linkkejä

Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Tiistai 26. huhtikuuta 2022

Ensisijainen valmistuminen (Todellinen)

Perjantai 19. joulukuuta 2025

Opintojen valmistuminen (Todellinen)

Tiistai 30. kesäkuuta 2026

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Torstai 30. syyskuuta 2021

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Keskiviikko 13. lokakuuta 2021

Ensimmäinen Lähetetty (Todellinen)

Tiistai 26. lokakuuta 2021

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Torstai 12. marraskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Maanantai 19. lokakuuta 2026

Viimeksi vahvistettu

Torstai 1. lokakuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Joo

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Yhdysvalloissa valmistettu ja sieltä viety tuote

Joo

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa